PMID- 16699287
OWN - NLM
STAT- MEDLINE
DCOM- 20060713
LR  - 20060613
IS  - 1018-2438 (Print)
IS  - 1018-2438 (Linking)
VI  - 140
IP  - 3
DP  - 2006
TI  - Allergen-specific polyclonal antibodies reduce allergic disease in a mouse model 
      of allergic asthma.
PG  - 261-9
AB  - BACKGROUND: Recombinant allergen-specific immunoglobulin G (IgG) antibody therapy 
      can reduce allergic asthma symptoms by inhibiting the immunoglobulin E 
      (IgE)-mediated allergic response. This study investigated the effect of 
      intranasally administered allergen-specific monoclonal (mAb) and polyclonal (pAb) 
      antibody on airway inflammation and hyperresponsiveness (AHR) in a mouse model of 
      human asthma. METHODS: Ovalbumin (OVA)-specific IgG2b antibodies were generated 
      by phage display using spleens from OVA-immunized mice, and screening against OVA 
      and finally expressed in CHO cells. Sensitized mice were treated intranasally 
      with either a recombinant anti-OVA mAb (gc32) or a polyclonal preparation 
      comprising seven selected antibodies (including gc32). Control mice received 
      diluent only, OVA only, a control polymeric IgG or dexamethasone. Following 
      challenge with nebulized OVA, investigators assessed airway inflammation by 
      histology and cellular composition of the bronchoalveolar fluid, and 
      methacholine-induced airway hyperresponsiveness (AHR). Serum levels of total and 
      OVA-specific IgE were measured by ELISA. RESULTS: Sensitized mice developed 
      airway inflammation and AHR in response to OVA challenge. Intranasally 
      administered OVA-specific murine polyclonal or monoclonal IgG2b antibodies both 
      reduced OVA-induced lung inflammation. Polyclonal, but not anti-OVA mAb, also 
      reduced AHR and eosinophil influx into the airway lumen. Both anti-OVA antibody 
      preparations reduced levels of specific IgE with no effect on total IgE levels. 
      CONCLUSIONS: Intranasal treatment with allergen-specific pAb reduces pulmonary 
      inflammation and AHR in a mouse model of allergic asthma, but allergen-specific 
      mAb reduces inflammation only. Allergen-specific recombinant pAb offers a 
      potentially valuable therapeutic approach to the management of allergic asthma.
FAU - Moerch, Ulrik
AU  - Moerch U
AD  - Symphogen A/S, Elektrovej, Lyngby, Denmark.
FAU - Haahr Hansen, Margit
AU  - Haahr Hansen M
FAU - Vest Hansen, Nils Jakob
AU  - Vest Hansen NJ
FAU - Rasmussen, Lone Kjaer
AU  - Rasmussen LK
FAU - Oleksiewicz, Martin B
AU  - Oleksiewicz MB
FAU - Frandsen, Torben P
AU  - Frandsen TP
FAU - Haurum, John S
AU  - Haurum JS
FAU - Bregenholt, Soren
AU  - Bregenholt S
LA  - eng
PT  - Journal Article
DEP - 20060511
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Antibodies)
RN  - 0 (Recombinant Proteins)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Administration, Intranasal
MH  - Animals
MH  - Antibodies/administration & dosage/immunology/*therapeutic use
MH  - Antibody Specificity
MH  - Asthma/*immunology/*therapy
MH  - Bronchoalveolar Lavage Fluid/cytology
MH  - Cell Count
MH  - Disease Models, Animal
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Histocytochemistry
MH  - Hypersensitivity, Immediate/immunology/prevention & control
MH  - Immunoglobulin E/blood
MH  - Immunotherapy/*methods/standards
MH  - Lung/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/immunology
MH  - Recombinant Proteins/administration & dosage/therapeutic use
EDAT- 2006/05/16 09:00
MHDA- 2006/07/14 09:00
CRDT- 2006/05/16 09:00
PHST- 2005/03/22 00:00 [received]
PHST- 2006/01/10 00:00 [accepted]
PHST- 2006/05/16 09:00 [pubmed]
PHST- 2006/07/14 09:00 [medline]
PHST- 2006/05/16 09:00 [entrez]
AID - 93283 [pii]
AID - 10.1159/000093283 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2006;140(3):261-9. doi: 10.1159/000093283. Epub 2006 
      May 11.